E2022 Patch Formulation Multiple Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

February 29, 2012

Conditions
Healthy
Interventions
DRUG

E2022

The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.

DRUG

Placebo

Matching Placebo tablets and tape

Trial Locations (1)

Unknown

Kagoshima

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01450839 - E2022 Patch Formulation Multiple Dose Study | Biotech Hunter | Biotech Hunter